Floatz logo

N-DESMETHYL-4-HYDROXYTAMOXIFEN

Gynecologic

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Gynecologic cohort.

Asset / SponsorPhaseRating
Bxcl501
Udayana University
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Udayana University
Phase 4BB
Carboplatin
Wenjun Cheng
Phase 3BB
Metformin
M.D. Anderson Cancer Center
Phase 3BB
DEXAMETHASONE
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B

View all 12 →

Same molecule, other indications

N-DESMETHYL-4-HYDROXYTAMOXIFEN is also rated in:

Bipolar 1 DisorderDormant
B
Indicative ·
62 / 100
View asset →
bipolar I disorderDormant
B
Indicative ·
60 / 100
View asset →
invasive breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →